Partners & Business Development

Cempra is focused on the clinical development of its two lead clinical anti-infective candidates, TAKSTA and solithromycin (CEM-101). TAKSTA (sodium fusidate, CEM-102) has completed Phase II trials in aBSSSI and we are planning Phase III clinical trials versus linezolid for this indication, including those caused by methicillin-resistant S. aureus (MRSA). We are also planning a Phase II trial with TAKSTA as a treamt for prosthetic joint infections.

Solithromycin is a novel, potent, orally-active fluoroketolide with a broad spectrum of activity against S. pneumoniae, including macrolide-resistant strains, atypical bacteria such as Mycoplasma and Legionella, M. avium, biodefense-relevant pathogens and Plasmodium falciparum. Solithromycin is the first macrolide since azithromycin to have the potential for both oral and IV dosing. Phase II clinical trials, with the oral formulation, in moderate-to-moderately severe community-acquired bacterial pneumonia have been initiated. The IV formulation is in a Phase I clinical trial.

Solithromycin, was selected from a library of over 500 macrolides licensed from Optimer Pharmaceuticals.

In addition to solithromycin, promising lead candidates for treating anti-inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), late stage asthma and psoriasis, endocrine diseases and gastrointestinal motility disorders have also been identified and are available for partnering.

To explore business opportunities with Cempra, please contact:


Carl Foster
919-313-6614
cfoster@cempra.com